Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07451769 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Selective Activation of the Adrenomedullin Receptors in Migraine

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Mar 10, 2026 to Mar 12, 2026
    • Site details revised
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.
Trial Details
NCT Number NCT07451769
Lead Sponsor Danish Headache Center
Conditions
(from sponsor)		 Migraine, Brain Diseases, Central Nervous System Diseases, Adrenomedullin, Pain, Peptides, Neuropeptides, Signs and Symptoms
Related terms Brain Diseases, Central Nervous System Diseases, Migraine Disorders, Pain, Signs and Symptoms
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov